alimemazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2749 84-96-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alimemazine
  • alimemazine tartrate
  • temaril
  • trimeprazine tartrate
  • trimeprazine
  • alimezine
  • methylpromazine
  • teralene
A phenothiazine derivative that is used as an antipruritic.
  • Molecular weight: 298.45
  • Formula: C18H22N2S
  • CLOGP: 5
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.55
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA ALLERGAN HERBERT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 1163.82 42.07 384 4798 64560 46616320
Intentional self-injury 1112.20 42.07 297 4885 23869 46657011
Poisoning deliberate 351.53 42.07 95 5087 7831 46673049
Coma 336.21 42.07 152 5030 58197 46622683
Somnolence 219.11 42.07 162 5020 156359 46524521
Tachycardia 145.53 42.07 106 5076 99516 46581364
Suicide attempt 137.62 42.07 82 5100 54954 46625926
Bradypnoea 127.93 42.07 35 5147 3004 46677876
Electrocardiogram QT prolonged 119.33 42.07 73 5109 51252 46629628
Toxicity to various agents 115.23 42.07 129 5053 211637 46469243
Depressed level of consciousness 106.34 42.07 66 5116 47503 46633377
Mydriasis 92.05 42.07 37 5145 10516 46670364
Akathisia 84.82 42.07 32 5150 7682 46673198
Hepatocellular injury 73.72 42.07 44 5138 29478 46651402
Altered state of consciousness 64.08 42.07 37 5145 23311 46657569
Pneumonia aspiration 63.44 42.07 41 5141 31564 46649316
Bladder dilatation 57.61 42.07 14 5168 749 46680131
Hypothermia 55.26 42.07 27 5155 12156 46668724
Extrapyramidal disorder 54.20 42.07 26 5156 11242 46669638
Hypercapnic coma 52.64 42.07 10 5172 162 46680718
Drug dependence 50.54 42.07 30 5152 19871 46661009
Alkalosis hypochloraemic 47.02 42.07 9 5173 152 46680728
Pyramidal tract syndrome 46.02 42.07 10 5172 324 46680556
Thymus disorder 44.81 42.07 9 5173 197 46680683
Suicidal ideation 44.34 42.07 42 5140 56340 46624540
Cardio-respiratory arrest 44.07 42.07 43 5139 59826 46621054
Rhabdomyolysis 42.41 42.07 36 5146 41873 46639007

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 550.82 33.59 200 3451 40249 29908578
Poisoning deliberate 247.22 33.59 69 3582 5835 29942992
Intentional overdose 213.84 33.59 103 3548 41378 29907449
Intentional self-injury 198.43 33.59 71 3580 13461 29935366
Somnolence 107.60 33.59 91 3560 96672 29852155
Toxicity to various agents 98.44 33.59 114 3537 177069 29771758
Electrocardiogram QT prolonged 86.50 33.59 54 3597 35781 29913046
Suicide attempt 65.92 33.59 46 3605 36651 29912176
Extrapyramidal disorder 62.38 33.59 29 3622 10664 29938163
Miosis 57.84 33.59 25 3626 7751 29941076
Tachycardia 57.59 33.59 57 3594 73682 29875145
Hepatocellular injury 53.03 33.59 35 3616 25436 29923391
Rhabdomyolysis 51.21 33.59 50 3601 63530 29885297
Hypothermia 43.85 33.59 22 3629 9545 29939282
Pneumonia aspiration 42.77 33.59 36 3615 37744 29911083
Sinus tachycardia 41.52 33.59 25 3626 15479 29933348
Depressed level of consciousness 40.37 33.59 35 3616 38187 29910640
Chemical submission 37.01 33.59 6 3645 32 29948795
Faecaloma 35.51 33.59 15 3636 4390 29944437

Pharmacologic Action:

SourceCodeDescription
ATC R06AD01 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Phenothiazine derivatives
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Angioedema indication 41291007 DOID:1558
General anesthesia indication 50697003
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 3.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST CHEMBL CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.90 CHEMBL

External reference:

IDSource
4019960 VUID
N0000148045 NUI
D02245 KEGG_DRUG
4330-99-8 SECONDARY_CAS_RN
4018016 VANDF
4019960 VANDF
C0041031 UMLSCUI
CHEBI:9725 CHEBI
CHEMBL829 ChEMBL_ID
CHEMBL3989885 ChEMBL_ID
DB01246 DRUGBANK_ID
CHEMBL1713082 ChEMBL_ID
5574 PUBCHEM_CID
D014291 MESH_DESCRIPTOR_UI
7237 IUPHAR_LIGAND_ID
C031242 MESH_SUPPLEMENTAL_RECORD_UI
706 INN_ID
76H78MJJ52 UNII
10825 RXNORM
2318 MMSL
5629 MMSL
d00788 MMSL
001535 NDDF
001536 NDDF
387471006 SNOMEDCT_US
52803004 SNOMEDCT_US
8109005 SNOMEDCT_US

Pharmaceutical products:

None